Patents Issued in March 17, 2020
  • Patent number: 10588863
    Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: March 17, 2020
    Assignee: KASHIV BIOSCIENCES, LLC
    Inventors: Siva Ram Kiran Vaka, Namdev B. Shelke, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
  • Patent number: 10588864
    Abstract: Disclosed are pharmaceutical particulates which release a pharmaceutical compound into the colon following oral administration. A particulate comprises a core comprising a pharmaceutical compound, an inner coating surrounding the core, wherein the inner coating comprises a pharmaceutically acceptable polysaccharide that is susceptible to enzymatic digestion by one or more enzymes present colonic microflora, and an outer coating surrounding the inner coating, wherein the outer coating comprises a polymer which is stable at upper gastrointestinal pH but can dissolve at pH>6. The core of a particulate can further comprise an excipient such as a diluent, a binder, a disintegrant, a lubricant, a glidant or a combination thereof. Particulates can comprise pharmaceutical compounds for treating colonic diseases such as C. difficile infection, ulcerative colitis, colon cancer, and Crohn's disease.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: March 17, 2020
    Assignee: Gateway Pharmaceuticals LLC
    Inventor: Lianli Li
  • Patent number: 10588865
    Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: March 17, 2020
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Patent number: 10588866
    Abstract: The present invention provides a delivery system which improves the stability, solubility and permeability of certain types of biologically active compounds in the gut after oral consumption. The delivery system comprises carrier granule comprising an agglomeration of solid lipid particles and a biologically active compound. The biologically active compound may be used with the delivery system to treat illnesses relating to inflammation, oxidation, or protein aggregation where a therapeutic blood and tissue level is required for treating the illness.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: March 17, 2020
    Assignee: Verdure Sciences
    Inventors: Lal Hingorani, Blake Ebersole
  • Patent number: 10588867
    Abstract: Nanoparticles are provided comprising an inner core comprising a non-cellular material, and an outer surface comprising a bacterial membrane, e.g., a bacterial membrane derived from a bacteria outer membrane vesicle. Also provided are compositions, e.g., medicament delivery systems and pharmaceutical compositions, comprising the present nanoparticles. Also provided are uses of the present nanoparticles, pharmaceutical compositions and medicament delivery systems for treating and/or preventing a disease or condition, e.g., bacterial infection, in a subject.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of California
    Inventors: Liangfang Zhang, Weiwei Gao, Ronnie H. Fang, Che-Ming Jack Hu
  • Patent number: 10588868
    Abstract: Systems and methods provide sugar alcohol to heat stressed ruminants to improve performance. During periods of high temperature or humidity, heat stressed ruminants may exhibit decreased dry matter intake, and in response, an effective amount of sugar alcohol such as sorbitol may be provided in the ruminant diet to cause performance to increase, which may include increased milk yield, improved feed efficiency or both compared to heat stressed dairy cattle without sugar alcohol in the diet.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: March 17, 2020
    Assignee: PURINA ANIMAL NUTRITION LLC
    Inventors: Bill L. Miller, Jill A. Davidson, Cindie M. Luhman
  • Patent number: 10588869
    Abstract: Transdermal delivery devices for the delivery of cannabidiol (CBD) are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the hacking material. In either design, the CBD may be provided as a pure compound or as a component of a cannabis oil.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: March 17, 2020
    Assignee: Life Tech Global, LLC
    Inventor: Ludwig Weimann
  • Patent number: 10588870
    Abstract: A cannabinoid active agent containing formulation comprising the active agent, an HFA propellant, optionally a terpenoid, and optionally a co-solvent is disclosed. At least two cannabinoids, each of which is required to be present in amounts of at least 20% of the total cannabinoid content of formulation are required to be present. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 40° C.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 17, 2020
    Assignee: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Patent number: 10588871
    Abstract: Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: March 17, 2020
    Assignee: NEXZOL PHARMA, INC.
    Inventors: Joseph M. Fracassi, Thomas J. Scarlata
  • Patent number: 10588872
    Abstract: An anise flavored liquid medication. The liquid medication contains phenylephrine and an anethole analog that is substantially free of aldehyde groups. In one example, the anethole analog can be 1-methoxy-4-n-propylbenzene.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: March 17, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Allyn Michael Kaufmann, James Carl Grimm, Chelsay Lynn Brewster, Thomas Edward Huetter
  • Patent number: 10588873
    Abstract: Aqueous, topical compositions contain an allylamine or an azole as an antifungal agent together with a lactate ester, an organic acid (pKa 3.8-5), ethanol, water, and a cationic galactomannan gum.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: March 17, 2020
    Assignee: Exodos Life Sciences LP
    Inventors: Servet Buyuktimkin, Nadir Buyuktimkin, James L. Yeager
  • Patent number: 10588874
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 17, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Patent number: 10588875
    Abstract: The present invention relates to an oral composition showing increased adsorption performance of an oil-soluble medicinal ingredient such as glycyrrhetinic acid and tocopherol to the gums and oral mucosa. The invention relates to an oral composition comprising the following ingredients (A), (B), (C), and (D): (A) 0.01 mass % or more and 2.5 mass % or less of one or more oil-soluble medicinal ingredients selected from the group consisting of glycyrrhetinic acid, tocopherol, and a tocopherol derivative; (B) 4 mass % or more and 30 mass % or less of a higher alcohol having 12 or more and 22 or less carbon atoms comprising (b1) cetanol and (b2) stearyl alcohol; (C) 0.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: March 17, 2020
    Assignee: KAO CORPORATION
    Inventors: Noritaka Takahashi, Ikuhisa Ichimura, Takuya Asada, Susumu Nakatsu
  • Patent number: 10588876
    Abstract: Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the R-enantiomer are formulated to increase ketone body level in a subject. The non-racemic mixture of BHB is enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer sufficient to provide alternative benefits as discussed herein. In some aspects a composition for increasing ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 55% to 98% by enantiomeric equivalents of the R-beta-hydroxybutyrate and from about 45% to about 2% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 17, 2020
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 10588877
    Abstract: ?-hydroxybutyric acid in combination with ?-hydroxybutyrate salts are useful to induce ketosis, achieving blood ketone levels of (0.5-6.0 mmol/L), with or without dietary restriction, and without inducing harmfully high mineral loads in the blood. The combination of ?-hydroxybutyric acid and salt results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance & endurance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. These acid/salt mixtures are also useful for suppressing appetite, preventing epileptic seizures, and treating cancer.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: March 17, 2020
    Assignee: SavInd, Inc.
    Inventor: Patrick Arnold
  • Patent number: 10588878
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 17, 2020
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 10588879
    Abstract: A method of treating age-related macular degeneration. The method includes the step of administering orally or parenterally an effective amount of aurin tricarboxylic acid, aurin quadracarboxylic acid, and/or aurin hexacarboxylic acid, wherein the method excludes administration of components of aurin tricarboxylic acid complex of greater than or equal to 1 kilodalton in molecular weight.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: March 17, 2020
    Assignee: Aurin Biotech Inc.
    Inventors: Patrick L. McGeer, Moonhee Lee
  • Patent number: 10588880
    Abstract: In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Eiger BioPharmaceuticals, Inc.
    Inventors: Xiaofeng Xiong, David A. Cory
  • Patent number: 10588881
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: March 17, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10588882
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: March 17, 2020
    Assignee: SynAgile Corporation
    Inventors: Adam Heller, John Spiridigliozzi
  • Patent number: 10588883
    Abstract: Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines. The present invention refers to pharmaceutically acceptable compounds of Formula I, their salts and derivatives, where (a) and (b) can take any value between 0 and 14, (X) can be substituted by any atom or group of atoms with an atomic/molecular weight between 4 and 200 Da and (R) can be substituted by any atom or group of atoms with an atomic/molecular weight between 1 and 200 Da, for use as medicines.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: March 17, 2020
    Assignee: UNIVERSITAT DE LES ILLES BALEARS
    Inventors: Pablo Vicente Escribá Ruiz, Xavier Busquets Xaubet, Gwendolyn Barceló Coblijn, Victoria Lladó Cañellas, Rafael Álvarez Martínez, Silvia Teres Jiménez, Daniel López, Juana Barceló Estarellas, Julian Taylor Green, Gerardo Ávila Martín
  • Patent number: 10588884
    Abstract: The present disclosure provides, in part, modulators of prostate-specific G-protein receptor (OR51E2/PSGR) and methods of treating, preventing, and diagnosing prostate cancer using the same.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: March 17, 2020
    Assignee: Duke University
    Inventors: Tatjana Abaffy, Hiro Matsunami
  • Patent number: 10588885
    Abstract: The invention provides compositions comprising chlorogenic acid and methods for their use and manufacture in the treatment of Alzheimer's disease. The compositions can be formulated from botanical sources of chlorogenic acid including sunflower seed extract.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: March 17, 2020
    Assignee: Vidya Herbs, Inc.
    Inventor: Kodimule Shyam Prasad
  • Patent number: 10588886
    Abstract: The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 17, 2020
    Assignee: Enzychem Lifesciences Corporation
    Inventors: Ki-Young Sohn, Jae Wha Kim
  • Patent number: 10588887
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: March 17, 2020
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventor: Annabelle Gallois-Bernos
  • Patent number: 10588888
    Abstract: Disclosed herein are ?-glucosidase (GCase) chaperones and methods of using GCase chaperones in an individual in need thereof. GBA1 mutations lead to GCase deficiency and substrate accumulation, causing Gaucher disease. Currently, no FDA or EMA-approved therapeutic for neuronopathic Gaucher disease is available. Improved GCase activity in brain cells using a chaperone may reduce substrate accumulation and associated pathology. Disclosed herein are novel non-inhibitory chaperone compounds of GCase that have properties of a central nervous system drug. Those compounds effectively restored mutant GCase activity by stabilizing protein and enhancing lysosomal localization and may be useful for chaperone therapy to treat neuronopathic Gaucher disease and likely to Parkinson's disease.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: March 17, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Ying Sun, Zhaolin Wang
  • Patent number: 10588889
    Abstract: This application describes compounds and methods that can be used to treat, reverse, or avoid hyperalgesia.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: March 17, 2020
    Assignee: TREVENA, INC.
    Inventors: Conrad Cowan, Michael Koblish, Michael W. Lark
  • Patent number: 10588890
    Abstract: The invention is composition and methods that restore balance to the stress-related steroidal hormone cascade. Upon co-administration, the compounds of the invention restore balance to the cascade and promote or restore normal function in patients suffering from a disorder having a primary psychological stress component. The compositions include a selected combination of isoflavones, alpha lipoic acid, and L dopamine or a precursor thereof, and are preferably obtained from the natural sources disclosed herein. The uses of the invention include administration of the disclosed compositions to patients suffering from PTSD, fibromyalgia, endometriosis, and other disorders having a common chronic stress component.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 17, 2020
    Assignee: BIOMMUNITY, INC.
    Inventor: Paul G. Emerson
  • Patent number: 10588891
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
  • Patent number: 10588892
    Abstract: The present invention relates to a pharmaceutical composition comprising a physical mixture of sacubitril sodium and valsartan disodium, wherein the X-ray powder diffraction pattern of valsartan disodium comprises characteristic peaks at the following 2 theta (±0.2) angles: 4.70°, 9.29°, 22.34°, measured using a Cu K? radiation. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of heart failure.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 17, 2020
    Assignee: SYNTHON B.V.
    Inventors: Bohumil Dymacek, Marta Vivancos Martinez, Luis Nogueiras Nieto, Lisardo Alvarez Fernandez, Rohit Kumar, Jose Velada Calzada, Petr Mitas
  • Patent number: 10588893
    Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: March 17, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihiro Murakami, Hitoshi Matsushita, Kengo Matsumoto, Minoru Okada, Yohei Yuki, Noriyuki Koyama, Naohiko Kanai
  • Patent number: 10588894
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: March 17, 2020
    Assignee: SHY Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Patent number: 10588895
    Abstract: Provided is a method for treating chronic obstructive pulmonary disease or chronic bronchitis, or inhibiting bronchospasm, which method comprises use of a powder inhaler to administer to a human patient in need of such treatment an effective amount of a powder inhalant, wherein the powder inhalant comprises 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 17, 2020
    Assignee: ALMIRALL, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Patent number: 10588896
    Abstract: The invention relates to pyridine-3,5-bis-thiocyanates which are new active substances for the treatment and prevention of retroviral infections and secondary diseases thereof, in particular HIV infections and AIDS, from the group of deubiquitinase inhibitors. Administration of the compounds of the invention increases the immunogenicity of viral proteins and thus the antiviral response.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: March 17, 2020
    Assignee: IMMUNOLOGIK GMBH
    Inventors: Ulrich Schubert, Christian Setz, Wolfgang Brysch, Jörg Von Wegerer
  • Patent number: 10588897
    Abstract: Described herein are assays for identifying piericidins and piericidin compositions.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of California
    Inventors: Victoria Auerbach Stone, Roger G. Linington, Weng Ruh Wong, Miles C. Duncan
  • Patent number: 10588898
    Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: March 17, 2020
    Assignee: TREVENA, INC.
    Inventors: Dennis Yamashita, Dimitar Gotchev, Philip Pitis, Xiao-Tao Chen, Guodong Liu, Catherine C. K. Yuan
  • Patent number: 10588899
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: March 17, 2020
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10588900
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: March 17, 2020
    Assignee: PHARMAKEA, INC.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson
  • Patent number: 10588901
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: March 17, 2020
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Patent number: 10588902
    Abstract: The present invention relates to the use of camptothecin derivatives as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: March 17, 2020
    Assignee: OyaGen, Inc.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • Patent number: 10588903
    Abstract: Compositions and methods are described in which the topical application of a toll-like receptor 7 agonist or a toll-like receptor 9 agonist at or near a subdermal vaccination site provides an enhanced response to the vaccination. The enhanced response can be an elevated antibody titer relative to an untreated but vaccinated subject, and/or development of cross-species immunity to species not present in the vaccinating composition.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: March 17, 2020
    Assignees: EMV ENHANCE (HK) LIMITED, VERSITECH LIMITED
    Inventors: Fan Ngai Hung, Jinxia Zhang, Kai Wang Kelvin To, Johnson Yiu-Nam Lau, Kwok Yung Yuen
  • Patent number: 10588904
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 17, 2020
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • Patent number: 10588905
    Abstract: Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: March 17, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Craig Erickson, Tori Lynn Schaefer
  • Patent number: 10588906
    Abstract: Provided herein is a method of preventing hair loss or promoting hair growth, the method including administering an effective amount of a PDE 3 inhibitor. More particularly, when the method of the present disclosure is used, an excellent hair loss prevention or hair growth promotion effect is obtained by inhibiting the activity of PDE 3.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 17, 2020
    Assignee: SEOUL NATIONAL UNIVERSITY HOSPITAL
    Inventors: Ohsang Kwon, Hye-In Choi, Seong Jin Jo, Kyu Han Kim
  • Patent number: 10588907
    Abstract: The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 17, 2020
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
  • Patent number: 10588908
    Abstract: A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof, or a combination thereof.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: March 17, 2020
    Assignee: Loxo Oncology, Inc.
    Inventors: Michael Cox, Nisha Nanda
  • Patent number: 10588909
    Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: March 17, 2020
    Assignees: Taivex Therapeutics Corporation, Development Center For Biotechnology
    Inventors: Jiann-Jyh Huang, Shih-Hsien Chuang, Ying-Shuan Eda Lee, Yu-Ling Huang, Johnson Lau
  • Patent number: 10588910
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating pulmonary arterial hypertension, which comprises an epidithiodioxopiperazine (ETP) compound or a derivative thereof, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: March 17, 2020
    Assignee: Vasthera Co. Ltd.
    Inventors: Sang Won Kang, Ki Hwan Kwon
  • Patent number: 10588911
    Abstract: The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating for use in treating a condition selected from Alzheimer's disease (AD), Parkinson's Diseases (PD) and vascular dementia (VD).
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 17, 2020
    Assignee: REGENERA PHARMA LTD.
    Inventors: Zadik Hazan, Konstantin Adamsky, Andre C. B. Lucassen, Nurit Novak
  • Patent number: 10588912
    Abstract: The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: March 17, 2020
    Assignee: Havah Therapeutics Pty Ltd
    Inventor: Stephen Nigel Birrell